VNUT inhibition, used as a positive control owing to its established ability to suppress ATP-derived eAdo release [4], resulted in similar improvements, supporting the relevance of purinergic signaling in MASLD progression. The gene discussed is SLC17A9; the disease is metabolic dysfunction-associated steatotic liver disease.